Elevation Oncology, Inc. (ELEV) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Boston, NY, アメリカ. 現CEOは Joseph J. Ferra Jr..
ELEV を有する IPO日 2021-06-25, 34 名の正社員, に上場 NASDAQ Global Select, 時価総額 $21.63M.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
